Per Eystein Lonning

List of Publications by Year
in descending order

185 papers	37,102 citations	57681 46 h-index	5347 170 g-index
191 all docs	191 docs citations	191 times ranked	29252 citing authors

#	Article	IF	Citations
1	C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer. Nature Communications, 2022, 13, 69.	5.8	16
2	Simultaneous Quantification of Aromatase Inhibitors and Estrogens in Postmenopausal Breast Cancer Patients. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1368-1374.	1.8	3
3	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.. Journal of Clinical Oncology, 2022, 40, e13634-e13634.	0.8	2
4	Constitutional BRCA1 methylation and risk of incident triple-negative breast cancer and high-grade serous ovarian cancer.. Journal of Clinical Oncology, 2022, 40, 10509-10509.	0.8	1
5	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology, 2021, 32, 240-249.	0.6	115
6	Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?. Trends in Cancer, 2021, 7, 181-185.	3.8	1
7	Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. Gene, 2021, 793, 145747.	1.0	7
8	An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range. Journal of the Endocrine Society, 2020, 4, bvaa047.	0.1	17
9	Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. Cancer Research, 2020, 80, 2163-2174.	0.4	8
10	Constitutional Mosaic Epimutations â€“ a hidden cause of cancer?. Cell Stress, 2019, 3, 118-135.	1.4	22
11	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. Breast Cancer Research and Treatment, 2018, 168, 169-178.	1.1	3
12	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 87-100.	5.1	307
13	NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. Breast Cancer Research, 2018, 20, 120.	2.2	85
14	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. Annals of Internal Medicine, 2018, 168, 326.	2.0	37
15	Patterns of genomic evolution in advanced melanoma. Nature Communications, 2018, 9, 2665.	5.8	62
16	MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. BMC Cancer, 2017, 17, 97.	1.1	14
17	The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-âˆ†5 in Breast Cancer Cells. Translational Oncology, 2017, 10, 806-817.	1.7	3
18	Comment on â€œTowards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsiesâ€•by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, Lab Chip, 2017, 17, 1594. Lab on A Chip, 2017, 17, 3186-3187.	3.1	3

#	Article	IF	Citations
19	Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. BMC Cell Biology, 2017, 18, 17.	3.0	11
20	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. Oncotarget, 2017, 8, 41227-41241.	0.8	16
21	MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. Scientific Reports, 2016, 6, 33153.	1.6	8
22	Impact of <scp> KRAS </scp> , <scp> BRAF </scp> , <scp> PIK3CA </scp> , <scp> TP5 3 </scp> status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. International Journal of Cancer, 2016, 139, 647-656.	2.3	79
23	Prevalence of the CHEK2 R95* germline mutation. Hereditary Cancer in Clinical Practice, 2016, 14, 19.	0.6	6
24	Comments on paper: â€œQuantitative determination of estrone by liquid chromatographyâ€“tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal womenâ€•by Vihma et al.. Journal of Steroid Biochemistry and Molecular Biology, 2016, 159, 72.	1.2	0
25	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. Journal of Clinical Oncology, 2016, 34, 1580-1583.	0.8	26
26	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. Journal of Clinical Oncology, 2016, 34, 555-555.	0.8	1
27	Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. Oncotarget, 2016, 7, 28637-28646.	0.8	22
28	MDM4 SNP34091 (rs4245739) and its effect on breastâ€, colonâ€, lungâ€, and prostate cancer risk. Cancer Medicine, 2015, 4, 1901-1907.	1.3	33
29	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. Journal of Investigative Dermatology, 2015, 135, 1820-1828.	0.3	46
30	Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. International Journal of Cancer, 2015, 137, 96-103.	2.3	27
31	Concomitant inactivation of the p53â€•and pRBâ€•functional pathways predicts resistance to DNA damaging drugs in breast cancer inÂvivo. Molecular Oncology, 2015, 9, 1553-1564.	2.1	23
32	Normal breast tissue estrogen levels. Maturitas, 2015, 81, 327.	1.0	0
33	Prognostic and predictive value of ERÎ²1 and ERÎ²2 in the Intergroup Exemestane Study (IES)â€”first results from PathIES. Annals of Oncology, 2015, 26, 1890-1897.	0.6	11
34	Estradiol measurement in translational studies of breast cancer. Steroids, 2015, 99, 26-31.	0.8	13
35	TP53status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. Acta OncolÃ³gica, 2014, 53, 1347-1355.	0.8	14
36	The multitude of molecular analyses in cancer: the opening of Pandoraâ€™s box. Genome Biology, 2014, 15, 447.	3.8	12

#	Article	IF	Citations
37	Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. European Journal of Cancer, 2014, 50, 1055-1064.	1.3	35
38	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. Expert Opinion on Pharmacotherapy, 2014, 15, 681-700.	0.9	41
39	Effects of SNP variants in the 17Î²-HSD2 and 17Î²-HSD7 genes and 17Î²-HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue. Journal of Steroid Biochemistry and Molecular Biology, 2014, 143, 192-198.	1.2	8
40	Abstract 1878: Performance comparison of BRAF V600E detection assays in malignant melanoma and colorectal cancer specimens. , 2014, , .		1
41	Genomic heterogeneity in primary breast cancer: Clinical implications.. Journal of Clinical Oncology, 2014, 32, 11004-11004.	0.8	1
42	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). Oncotarget, 2014, 5, 8223-8234.	0.8	22
43	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. Clinical and Experimental Metastasis, 2013, 30, 867-876.	1.7	16
44	Lapatinib in early breast cancerâ€"questions to be resolved. Lancet Oncology, The, 2013, 14, 11-12.	5.1	46
45	Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. Oncogene, 2013, 32, 5315-5330.	2.6	44
46	Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2â€“ locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. Journal of Clinical Oncology, 2013, 31, TPS650-TPS650.	0.8	1
47	Abstract 3139: Identification and functional studies of p53 mutants detected in breast cancers after chemotherapy treatment.. , 2013, , .		0
48	Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. Therapeutic Advances in Medical Oncology, 2012, 4, 127-137.	1.4	26
49	Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research, 2012, 14, R47.	2.2	58
50	Chemosensitivity and p53; new tricks by an old dog. Breast Cancer Research, 2012, 14, 325.	2.2	4
51	Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology, 2012, 128, 69-75.	1.2	15
52	P53 and its molecular basis to chemoresistance in breast cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S23-S30.	1.5	57
53	Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. NMR in Biomedicine, 2012, 25, 1033-1042.	1.6	45
54	Abstract 3704: Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension in a single-arm Phase II study. , 2012, , .		0

#	Article	IF	Citations
55	Abstract 863: Tyrosine kinase activity profiling of metastatic malignant melanoma: Identification of possible therapeutic targets and markers predicting response to therapy. , 2012, , .		0
56	Recent data on intratumor estrogens in breast cancer. Steroids, 2011, 76, 786-791.	0.8	28
57	Alterations of the retinoblastoma gene in metastatic breast cancer. Clinical and Experimental Metastasis, 2011, 28, 319-326.	1.7	13
58	Effects of theMDM2promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. Transcription, 2011, 2, 207-210.	1.7	34
59	RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. Annals of Oncology, 2011, 22, 2208-2215.	0.6	38
60	Exploring Breast Cancer Estrogen Disposition: The Basis for Endocrine Manipulation. Clinical Cancer Research, 2011, 17, 4948-4958.	3.2	58
61	The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. Annals of Oncology, 2011, 22, 503-514.	0.6	56
62	Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. PLoS ONE, 2011, 6, e19249.	1.1	65
63	MDM2promoter SNP285 and SNP309; phylogeny and impact on cancer risk. Oncotarget, 2011, 2, 251-258.	0.8	39
64	Intratumoral Estrogen Disposition in Breast Cancer. Clinical Cancer Research, 2010, 16, 1790-1801.	3.2	92
65	Molecular basis for therapy resistance. Molecular Oncology, 2010, 4, 284-300.	2.1	37
66	Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: Of relevance to clinical understanding?. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 288-293.	1.2	12
67	Impact of aromatase inhibitors on bone health in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 294-299.	1.2	26
68	Breast cancer aromatase expression evaluated by the novel antibody 677: Correlations to intra-tumor estrogen levels and hormone receptor status. Journal of Steroid Biochemistry and Molecular Biology, 2010, 118, 237-241.	1.2	16
69	Are current development programs realising the full potential of new agents?. Breast Cancer Research, 2010, 12, S23.	2.2	0
70	Abstract 1092: Alterations of the retinoblastoma gene in stage III breast cancers. , 2010, , .		0
71	Additive endocrine therapy for advanced breast cancer â€“ back to the future. Acta OncolÃ³gica, 2009, 48, 1092-1101.	0.8	36
72	Molecular classes of breast cancer and their clinical relevance. Current Breast Cancer Reports, 2009, 1, 183-189.	0.5	0

#	Article	IF	Citations
73	Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. British Journal of Cancer, 2009, 101, 1253-1260.	2.9	39
74	Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. European Journal of Cancer, 2009, 45, 527-535.	1.3	51
75	Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. Journal of Steroid Biochemistry and Molecular Biology, 2009, 117, 31-41.	1.2	89
76	Tailored targeted therapy for all: a realistic and worthwhile objective?. Breast Cancer Research, 2009, 11, S7.	2.2	2
77	Strength and weakness of phase I to IV trials, with an emphasis on translational aspects. Breast Cancer Research, 2008, 10, S22.	2.2	7
78	Aromatase inhibitors: Assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. Journal of Steroid Biochemistry and Molecular Biology, 2008, 108, 196-202.	1.2	20
79	An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. Journal of Steroid Biochemistry and Molecular Biology, 2008, 109, 90-95.	1.2	62
80	Letrozole is Superior to Anastrozole in Suppressing Breast Cancer Tissue and Plasma Estrogen Levels. Clinical Cancer Research, 2008, 14, 6330-6335.	3.2	121
81	Indications and limitations of third-generation aromatase inhibitors. Expert Opinion on Investigational Drugs, 2008, 17, 723-739.	1.9	18
82	CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. PLoS ONE, 2008, 3, e3062.	1.1	74
83	Breast cancer prognostication and prediction: are we making progress?. Annals of Oncology, 2007, 18, viii3-viii7.	0.6	52
84	Amplification ofTOP2AandHER-2genes in breast cancers occurring in patients harbouringBRCA1germline mutations. Acta OncolÃ³gica, 2007, 46, 199-203.	0.8	12
85	Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. Acta OncolÃ³gica, 2007, 46, 153-164.	0.8	47
86	Breast cancer prognostication and prediction in the postgenomic era. Annals of Oncology, 2007, 18, 1293-1306.	0.6	55
87	Aromatase inhibitorsâ€"Socioeconomical issues. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 55-61.	1.2	2
88	Adjuvant Endocrine Treatment of Early Breast Cancer. Hematology/Oncology Clinics of North America, 2007, 21, 223-238.	0.9	15
89	P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. International Journal of Cancer, 2007, 120, 2749-2749.	2.3	1
90	Mutations and polymorphisms of thep21B transcript in breast cancer. International Journal of Cancer, 2007, 121, 908-910.	2.3	16

#	Article	IF	Citations
91	Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer, 2006, 42, 2968-2975.	1.3	92
92	Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. Breast Cancer Online: BCO, 2006, 9, 1-3.	0.1	0
93	Bone safety of aromatase inhibitors versus tamoxifen. International Journal of Gynecological Cancer, 2006, 16, 518-520.	1.2	18
94	Aromatase inhibitors as adjuvant treatment of breast cancer. Critical Reviews in Oncology/Hematology, 2006, 57, 53-61.	2.0	18
95	A novel type of deletion in theCDKN2A gene identified in a melanoma-prone family. Genes Chromosomes and Cancer, 2006, 45, 1155-1163.	1.5	22
96	Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer?. Nature Clinical Practice Oncology, 2006, 3, 356-357.	4.3	0
97	Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2â€“3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Annals of Oncology, 2006, 17, 217-225.	0.6	41
98	Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. Journal of Clinical Oncology, 2006, 24, 10532-10532.	0.8	4
99	Effects of Exemestane Administered for 2 Years Versus Placebo on Bone Mineral Density, Bone Biomarkers, and Plasma Lipids in Patients With Surgically Resected Early Breast Cancer. Journal of Clinical Oncology, 2005, 23, 5126-5137.	0.8	278
100	Aromatase inhibitors in the treatment of early and advanced breast cancer. Acta OncolÃ³gica, 2005, 44, 23-31.	0.8	27
101	Aromatase inhibitorsâ€”Socio-economical issues. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 137-142.	1.2	3
102	Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2005, 96, 415-422.	1.2	16
103	Exemestane for breast cancer prevention: a feasible strategy?. Clinical Cancer Research, 2005, 11, 918s-24s.	3.2	4
104	A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer. New England Journal of Medicine, 2004, 350, 1081-1092.	13.9	1,694
105	Aromatase inhibitors in breast cancer.. Endocrine-Related Cancer, 2004, 11, 179-189.	1.6	76
106	Clinical Pharmacokinetics of Aromatase Inhibitors and Inactivators. Clinical Pharmacokinetics, 2003, 42, 619-631.	1.6	17
107	Repeated observation of breast tumor subtypes in independent gene expression data sets. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8418-8423.	3.3	4,849
108	Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2003, 39, 438-446.	1.3	47

#	Article	IF	Citations
109	Comparison between aromatase inhibitors and sequential use. Journal of Steroid Biochemistry and Molecular Biology, 2003, 86, 275-282.	1.2	7
110	Aromatase Inhibitors and Inactivators for Breast Cancer Therapy. Drugs and Aging, 2002, 19, 277-298.	1.3	20
111	The role of aromatase inactivators in the treatment of breast cancer. International Journal of Clinical Oncology, 2002, 7, 265-270.	1.0	10
112	Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow's Challenges. Clinical Breast Cancer, 2001, 1, 297-308.	1.1	19
113	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 10869-10874.	3.3	9,721
114	Pharmacokinetics and metabolism of formestane in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2001, 77, 39-47.	1.2	23
115	Stepwise estrogen suppression manipulating the estrostat. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 127-132.	1.2	19
116	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment, 2001, 67, 111-116.	1.1	219
117	Exemestane: a review of its clinical efficacy and safety. Breast, 2001, 10, 198-208.	0.9	22
118	Microarrays in primary breast cancer--lessons from chemotherapy studies.. Endocrine-Related Cancer, 2001, 8, 259-263.	1.6	34
119	Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Research, 2001, 61, 2505-12.	0.4	240
120	The potential for aromatase inhibition in breast cancer prevention. Clinical Cancer Research, 2001, 7, 4423s-4428s; discussion 4411s-4412s.	3.2	5
121	Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial. Journal of Clinical Oncology, 2000, 18, 2234-2244.	0.8	302
122	Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene, 2000, 19, 1329-1333.	2.6	153
123	Molecular portraits of human breast tumours. Nature, 2000, 406, 747-752.	13.7	13,397
124	Clinico-pharmacological aspects of different hormone treatments. European Journal of Cancer, 2000, 36, 81-82.	1.3	14
125	Pharmacology and clinical experience with exemestane. Expert Opinion on Investigational Drugs, 2000, 9, 1897-1905.	1.9	24
126	Exemestane in Breast Cancer: Current Status and Future Directions. Clinical Breast Cancer, 2000, 1, S28-S33.	1.1	4

#	Article	IF	Citations
127	Is There a Growing Role for Endocrine Therapy in the Treatment of Breast Cancer?. Drugs, 2000, 60, 11-21.	4.9	4
128	Cross-resistance to different aromatase inhibitors in breast cancer treatment.. Endocrine-Related Cancer, 1999, 6, 251-257.	1.6	15
129	Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. Cancer Letters, 1999, 145, 73-77.	3.2	12
130	Exemestane. Drugs, 1999, 58, 681-682.	4.9	0
131	Pharmacological and clinical profile of anastrozole. Breast Cancer Research and Treatment, 1998, 49, S53-S57.	1.1	16
132	Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. Breast Cancer Research and Treatment, 1998, 49, S45-S52.	1.1	41
133	Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. British Journal of Cancer, 1998, 78, 12-15.	2.9	19
134	Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients. Cancer Chemotherapy and Pharmacology, 1998, 42, 46-52.	1.1	3
135	Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. Maturitas, 1998, 28, 259-265.	1.0	27
136	Influence of Droloxifene on Metastatic Breast Cancer as First-Line Endocrine Treatment. Acta OncolÃ³gica, 1998, 37, 365-368.	0.8	17
137	In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. Clinical Cancer Research, 1998, 4, 2089-93.	3.2	229
138	Anastrozole â€“ A New Generation in Aromatase Inhibition: Clinical Pharmacology. Oncology, 1997, 54, 11-14.	0.9	22
139	Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 1997, 63, 53-58.	1.2	18
140	Exemestane experience in breast cancer treatment. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 151-5.	1.2	7
141	Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. Journal of Steroid Biochemistry and Molecular Biology, 1997, 61, 255-60.	1.2	4
142	Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, pro-IGF-IIE, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 167-171.	1.2	25
143	Aromatase Inhibition for Breast Cancer Treatment. Acta OncolÃ³gica, 1996, 35, 38-43.	0.8	33
144	Insulin-Like Growth Factors in Breast Cancer. Acta OncolÃ³gica, 1996, 35, 19-22.	0.8	22

#	Article	IF	Citations
145	Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. Breast Cancer Research and Treatment, 1996, 39, 335-341.	1.1	47
146	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nature Medicine, 1996, 2, 811-814.	15.2	797
147	Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. British Journal of Cancer, 1996, 74, 1286-1291.	2.9	312
148	Determination of Droloxifene and Two Metabolites in Serum by High-Pressure Liquid Chromatography. Therapeutic Drug Monitoring, 1995, 17, 259-265.	1.0	12
149	Relations between sex hormones, sex hormone binding globulin, insulinâ€like growth factorâ€I and insulinâ€like growth factor binding proteinâ€I in postâ€menopausal breast cancer patients. Clinical Endocrinology, 1995, 42, 23-30.	1.2	65
150	Mechanisms of action of endocrine treatment in breast cancer. Critical Reviews in Oncology/Hematology, 1995, 21, 158-193.	2.0	45
151	Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. Journal of Endocrinology, 1995, 146, 359-363.	1.2	22
152	Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 193-195.	1.2	20
153	Paclitaxel and Docetaxel. Pharmacoeconomics, 1995, 8, 1-4.	1.7	1
154	A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 409-412.	1.2	47
155	Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 1995, 52, 491-496.	1.2	61
156	Systemic Therapy in Breast Cancer. Pharmacoeconomics, 1994, 5, 198-212.	1.7	17
157	Dose Response Evaluation. Clinical Pharmacokinetics, 1993, 25, 1-5.	1.6	4
158	Use of endocrine therapy to study the biology of breast cancer. Cancer Treatment Reviews, 1993, 19, 65-77.	3.4	1
159	Aromatase Inhibitors in Malignant Diseases of Aging. Drugs and Aging, 1992, 2, 530-545.	1.3	14
160	Clinical Pharmacokinetics of Endocrine Agents Used in Advanced Breast Cancer. Clinical Pharmacokinetics, 1992, 22, 327-358.	1.6	62
161	Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. Breast Cancer Research and Treatment, 1992, 23, 57-62.	1.1	30
162	Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. Cancer Research, 1992, 52, 4719-23.	0.4	77

#	Article	IF	Citations
163	Treatment of Early Breast Cancer with Conservation of the Breast a Review. Acta OncolÃ³gica, 1991, 30, 779-792.	0.8	8
164	The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. British Journal of Cancer, 1991, 63, 789-793.	2.9	77
165	Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology, 1991, 27, 367-372.	1.1	28
166	New Endocrine Drugs for Treatment of Advanced Breast Cancer. Acta OncolÃ³gica, 1990, 29, 379-386.	0.8	11
167	Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. Cancer Chemotherapy and Pharmacology, 1990, 26, 241-244.	1.1	26
168	Postmenopausal estrogen synthesis and metabolism: Alterations caused by aromatase inhibitors used for the treatment of breast cancer. The Journal of Steroid Biochemistry, 1990, 35, 355-366.	1.3	93
169	Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. Cancer Research, 1990, 50, 5851-7.	0.4	73
170	Treatment of breast cancer with aromatase inhibitors â€“ current status and future prospects. British Journal of Cancer, 1989, 60, 5-8.	2.9	15
171	Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. British Journal of Cancer, 1989, 60, 107-111.	2.9	55
172	Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. The Journal of Steroid Biochemistry, 1989, 32, 91-97.	1.3	37
173	Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. The Journal of Steroid Biochemistry, 1989, 33, 541-545.	1.3	26
174	Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. The Journal of Steroid Biochemistry, 1989, 33, 565-571.	1.3	21
175	Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin. The Journal of Steroid Biochemistry, 1989, 33, 631-635.	1.3	16
176	Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. The Journal of Steroid Biochemistry, 1989, 34, 551-553.	1.3	27
177	Mechanisms of Action of Aminoglutethimide as Endocrine Therapy of Breast Cancer. Drugs, 1988, 35, 685-710.	4.9	96
178	Alterations in the Metabolism of Oestrogens During Treatment with Aminoglutethimide in Breast Cancer Patients. Clinical Pharmacokinetics, 1987, 13, 393-406.	1.6	51
179	Accidental hypothermia Review of the literature. Acta Anaesthesiologica Scandinavica, 1986, 30, 601-613.	0.7	68
180	Determination of Warfarin in Human Plasma by High Performance Liquid Chromatography and Photodiode Array Detector. Therapeutic Drug Monitoring, 1985, 7, 329-335.	1.0	17

#	Article	IF	Citations
181	Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. Clinical Pharmacology and Therapeutics, 1984, 36, 796-802.	2.3	31
182	Treatment of Breast Carcinoma with Aminoglutethimide. Acta Radiologica Oncology, 1984, 23, 421-424.	0.5	16
183	Determination of Aminoglutethimide and N-Acetylaminoglutethimide in Human Plasma by Reversed-Phase Liquid Chromatography. Therapeutic Drug Monitoring, 1984, 6, 221-226.	1.0	14
184	The relation between cell proliferation and adenylate cyclase activity in grafts of 3-methylcholanthrene induced mouse uterine cervical tumors. Experientia, 1982, 38, 387-389.	1.2	0
185	EFFECT OF ESTRADIOL AND PROGESTERONE ON THE ADENYLATE CYCLASE ACTIVITY IN GRAFTS OF 3â€METHYLCHOLANTHRENE INDUCED CARCINOMAS IN THE MOUSE UTERINE CERVIX. Acta Pathologica Et Microbiologica Scandinavica Section A, Pathology, 1980, 88A, 111-118.	0.1	0